{"schema_version":"secwatch.filing_event.v1","accession":"0000318154-24-000042","form_type":"8-K","ticker":"AMGN","cik":"0000318154","company_name":"AMGEN INC","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.693613+00:00","generated_at":"2026-05-30T08:39:44.874918+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Amgen Q3 2024 revenue $8.5B (+23%), GAAP EPS $5.22 (+62%), non-GAAP EPS $5.58 (+13%)","bullets":["Total revenues $8.5B (+23% YoY); product sales grew 24% on 29% volume growth.","GAAP EPS $5.22 (+62%); non-GAAP EPS $5.58 (+13%).","Free cash flow $3.3B vs $2.5B in Q3 2023.","Rare disease portfolio contributed $1.2B in sales; 10 products had double-digit growth.","Non-GAAP operating income $4.0B; operating margin 49.6% (down 2.4 ppt)."],"urls":{"canonical":"https://secwatch.observer/filing/0000318154-24-000042","json":"https://secwatch.observer/filing/0000318154-24-000042.json","markdown":"https://secwatch.observer/filing/0000318154-24-000042.md","text":"https://secwatch.observer/filing/0000318154-24-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318154/000031815424000042/0000318154-24-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318154/000031815424000042/amgn-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:39:44.874918+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}